振东制药：在研项目阴道用乳杆菌二联活菌胶囊达到主要研究终点

Core Viewpoint - Zhendong Pharmaceutical announced that its associate company, Guangdong Longchuang Biopharmaceutical Co., Ltd., has achieved the primary research endpoint in the Phase III clinical trial of the "Vaginal Lactobacillus Dual Live Bacteria Capsule" [1] Group 1 - The Phase III clinical trial for the "Vaginal Lactobacillus Dual Live Bacteria Capsule" has reached its primary research endpoint [1] - The company plans to submit a communication application to the National Medical Products Administration (NMPA) for the marketing authorization of the product targeting bacterial vaginosis [1] - The company is actively promoting the market launch process for the "Vaginal Lactobacillus Dual Live Bacteria Capsule" [1]